Paradigmenwechsel in der Therapie viraler Hepatitiden

Schlüsselwörter

Hepatitis - Virushepatitis - direkt antivirale Therapie - HCV-Proteaseinhibitoren

Keywords

hepatitis - viral hepatitis - direct-acting antiviral therapy - HCV protease inhibitors

• Literatur

• 1 Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New Engl J Med 2011; 364: 1207-1217
• 2 Chan HLY, Thompson A, Martinot-Peignoux M et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011-A core group report. J Hepatol 2011; 55: 1121-1131
• 3 Chang MH, Chiu YC et al. Spontaneous clearance of hepatitis B surface antigen during the natural history of chronic hepatitis B virus infection. Hepatology 2011; 54: 711a-712a
• 4 Chayama K, Takahashi S, Toyota J et al. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders. Hepatology 2011; Oct 10; doi:
• 5 Cornberg M, Protzer U, Petersen J et al. Prophylaxis, diagnosis and therapy of hepatitis B virus infection – The German Guideline. Z Gastroenterol 2011; 49: 871-930
• 6 Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378: 73-85
• 7 Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New Engl J Med 2011; 364: 2405-2416
• 8 Jaroszewicz J, Ho H, Markova A et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antiviral Ther 2011; 16: 915-924
• 9 Kamar N, Rostaing L, Abravanel F et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology 2010; 139: 1612-1618
• 10 McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New Engl J Med 2009; 360: 1827-1838
• 11 Pischke S, Potthoff A, Hauroder B et al. [Hepatitis E virus infection: a paradigm shift?]. Dtsch Med Wochenschr 2010; 135: 1129-1133
• 12 Pischke S, Suneetha PV, Baechlein C et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transplant 2010; 16: 74-82
• 13 Poordad F, McCone J, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. New Engl J Med 2011; 364: 1195-1206
• 14 Sarrazin C, Berg T, Ross RS et al. Prophylaxis, diagnosis and therapy of hepatitis c virus (HCV) infection: The German Guidelines on the Management of HCV Infection. Z Gastroenterol 2010; 48: 289-351
• 15 Sherman KE. Response-guided telaprevir combination treatment for hepatitis C virus infection. New Engl J Med 2011; 365: 1551
• 16 Wedemeyer H, Yurdaydin C, Dalekos GN et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2010; 364: 322-331
• 17 Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. New Engl J Med 2011; 364: 2417-2428
• 18 Zhu FC, Zhang J, Zhang XF et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults. Lancet 2010; 376: 895-902